Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
GH
GUARDANT HEALTH, INC.
NASDAQ
$167.47
▲ UP 1.15% (1.91)

KEY STATISTICS

Market Cap$22.21 B
52w High$191.05
52w Low$61.00
Dividend Yield—
Frequency—
P/E-47.99
Volume1.52M
Shares Out.134.20M

COMPANY

LEADERSHIP

Helmy Eltoukhy
CHIEF EXECUTIVE
Helmy Eltoukhy

COMPENSATION 2026

Salary$1
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$11,590
Total$11,591

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 4, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
2,498

PRICE TARGET

Target High$225.00
Target Low$180.00
Target Median$200.00
Target Consensus$201.40

UPCOMING EARNINGS

DateOct 28, 2026
DayWednesday
Rev. Est.$350.60M
OCT
28
WED

ETFS HOLDING THIS STOCK

ETFS HOLDING
315
LISTED HERE
10
RANKED BY POSITION SIZE
VTS.AX
0.03%
4.0M
IWP
0.55%
644.7K
ARKG
4.73%
592.4K
SCHM
0.47%
403.4K
CGGR
0.26%
399.0K
FESM
0.51%
197.8K
TMSL
0.91%
165.2K
TGED.TO
2.05%
153.7K
FXH
2.30%
151.6K
PDP
1.69%
148.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
46.65%
HOLDERS
743
TOP 8 OF 743 · RANKED BY POSITION SIZE
Vanguard Group Inc
12.2M sh
$1.24B
Blackrock, Inc.
11.6M sh
$1.07B
Blackrock Inc.
11.2M sh
$324.55M
Price T Rowe Associates Inc /Md/
7.0M sh
$648.78M
Fmr LLC
5.5M sh
$823.41M
Invesco Ltd.
5.3M sh
$542.97M
Baillie Gifford & Co
5.1M sh
$320.38M
Capital International Investors
4.7M sh
$292.98M

PRICE

$167.47 ▲ UP 1.15% (+$1.91)
$167$168$1709:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM167.47

About Guardant Health, Inc.

https://guardanthealth.com ↗

Guardant Health is a precision oncology company providing blood-based tests, data analytics, and research platforms for cancer detection, treatment, and clinical trial connectivity globally.

INDUSTRY

Medical - Diagnostics & Research

A PRODUCT GUARDANT HEALTH, INC. IS KNOWN FOR

Shield™
Shield™

Shield™ is an FDA-approved blood-based colorectal cancer screening test utilizing AI for early detection, offering a less invasive alternative to colonoscopies and recognized as a TIME Best Invention of 2024.

COMPETITORS

COMPETITOR
ILMN COMPARE
NTRA COMPARE
QGEN COMPARE
TEM COMPARE

Guardant Health in 2025

SENTIMENT: + POSITIVE
Chris Freeman
EARNINGS · OCTOBER 29, 2025

Guardant Health Significantly Raises 2025 Revenue Guidance After Strong Q3 Performance, Signaling Accelerated Growth

Guardant Health announced robust third-quarter 2025 financial results, reporting a 39% increase in total revenue to $265.2 million compared to the prior year. Driven by strong performance across its Oncology, Screening, and Biopharma segments, the company significantly raised its full-year 2025 revenue guidance to a range of $965 to $970 million, up from the previously raised guidance of $915 to $925 million. This repeated upward revision underscored growing demand for its products, particularly the Shield screening test, and led to considerable investor and analyst attention.

PARTNERSHIP · Q3 2025 · IN PROGRESS

Guardant Health Forges Key Strategic Partnerships to Massively Scale Commercialization of Shield Blood Test

In 2025, Guardant Health executed a significant strategic shift to accelerate the adoption of its Shield colorectal cancer screening test by entering into major partnerships with national diagnostic laboratories, including Quest Diagnostics and PathGroup. This move dramatically expands Shield's market access to thousands of physicians and millions of patients, representing a pivotal change in its go-to-market strategy from relying solely on its own commercial infrastructure to leveraging established networks for rapid, widespread distribution.

Latest News

BUSINESS WIRE · OCT 8, 2026

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe's in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca's next-generation oral selective estrogen.

READ ARTICLE
EARLIER COVERAGE
BUSINESS WIRE · OCT 8, 2026

Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast wil.

READ ARTICLE
FXEMPIRE · OCT 5, 2026

Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250

Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.

READ ARTICLE
BUSINESS WIRE · OCT 5, 2026

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal™ blood test for molecular residual disease (MRD) detection and recurrence monitoring in patients wi.

READ ARTICLE
DEFENSE WORLD · OCT 4, 2026

Reviewing Guardant Health (NASDAQ:GH) & Privia Health Group (NASDAQ:PRVA)

Privia Health Group (NASDAQ: PRVA - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation. Analyst Ratings This is a summary of

READ ARTICLE

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 9
OVERWEIGHT 6
OUTPERFORM 5
20 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Guggenheim BUY UBS BUY BTIG BUY Morgan Stanley OVERWEIGHT Piper Sandler OVERWEIGHT Stephens & Co. OVERWEIGHT Stifel BUY

SECTORS PEERS

PEERPRICE
NTRA$389.00COMPARE
VTRS$17.54COMPARE
RVTY$154.00COMPARE
SOLV$87.30COMPARE
ASND$230.15COMPARE
BBIO$66.95COMPARE
ICLR$162.15COMPARE
EHC$124.56COMPARE

TRADES BY CONGRESS

SENATE TRADES
Sheldon Whitehouse
Sheldon Whitehouse
Purchase
2025-11-21
HOUSE TRADES
Donald Sternoff Beyer
Donald Sternoff Beyer
Sale (Full)
2022-02-28
 Donald Sternoff Beyer Jr.
Donald Sternoff Beyer Jr.
Sale (Full)
2022-02-28

INSIDER TRADES

★
DIRECTOR, OFFICER: CO-CHIEF EXECUTIVE OFFICER
Eltoukhy Helmy
Sale · 24.0K shares
2026-10-01
★
DIRECTOR, OFFICER: CO-CHIEF EXECUTIVE OFFICER
Eltoukhy Helmy
Sale · 9.7K shares
2026-10-01
★
DIRECTOR, OFFICER: CO-CHIEF EXECUTIVE OFFICER
Eltoukhy Helmy
Sale · 17.1K shares
2026-10-01
★
DIRECTOR, OFFICER: CO-CHIEF EXECUTIVE OFFICER
Eltoukhy Helmy
Purchase · 24.0K shares
2026-10-01